Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ChemoCentryx Gains Runway To Grow With Avacopan Approval

Oct 08 2021

• By Joseph Haas

FDA approved background, 3D rendering, blue street sign — ChemoCentryx obtains its first US approval with avacopan in vasculitis

Related Content

ChemoCentryx’s Avacopan May Need Another Trial After Tepid Advisory Committee Vote

May 07 2021

Roche Reveals Impact Of Multisource Biosimilar Competition

Apr 23 2020

ChemoCentryx Soars On Phase III Avacopan Data In ANCA Vasculitis

Nov 26 2019

Vifor Pharma: Targets Acquisitions As Pure-Play Strategy Delivers

Mar 14 2019

Related Companies

ChemoCentryx, Inc.

Roche Holding AG

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

GSK plc

CSL Vifor

Kissei Pharmaceutical Co., Ltd

Additional Topics

Approvals Commercial Business Strategies Launches Rare Diseases Renal BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window